A fiber-fed gut molecule may reverse fatty liver disease, mouse study finds

Gut bacteria are already known to shape how the body handles fat, but a new study identifies a specific molecular messenger behind that link, and shows that a common dietary lever, fiber, controls how much of it the body makes. Researchers reported in Gastro Hep Advances that gut bacteria in the group Bacteroidota produce a family of bioactive glycine lipids that appear to protect the liver from fatty buildup, with the effect traced down to mitochondrial function inside liver cells. The therapeutic result comes entirely from mice, but the molecules themselves also turned up in human liver tissue, a distinction the researchers are careful to keep separate.

Gut Bacteria's Glycine Lipids Turn Up in Mouse and Human Liver

The team, led by Liya Anto and Lidan Gao with senior author Christopher Blesso at the University of Connecticut, focused on three related compounds made by oral and gut Bacteroidota bacteria: a core molecule called Lipid 342, and two more complex relatives, Lipid 654 and Lipid 1256. Using targeted mass spectrometry, the researchers detected Lipid 654 and Lipid 1256 not just in the mouse gut, but circulating in mouse systemic and portal blood, moving through intestinal lymph, and present in mouse liver, and in human liver tissue as well. Earlier work from this research area, including a 2022 Journal of Lipid Research study, had already flagged these bacterial lipids as diet dependent modulators of liver injury. That human liver detail matters: it establishes that these bacterial lipids reach the human liver in real life, even though what happens when you dose them therapeutically has only been tested in mice so far.

Fiber, Not Just Diet Quality, Controls How Much of the Lipid You Make

A Western style high fat diet lowered both fecal and hepatic levels of these glycine lipids in the mice, while adding fermentable fiber to the diet reversed that, restoring fecal glycine lipid levels by roughly sevenfold. Inside the liver, higher glycine lipid content tracked with lower liver triglycerides, the fat that builds up in metabolic dysfunction associated steatotic liver disease, or MASLD, formerly called NAFLD. That inverse relationship, consistent with the diet dependence described in the full text of the 2022 Journal of Lipid Research paper, is what pointed the researchers toward testing the lipids directly as a treatment rather than just a biomarker.

An 8 Week Treatment Reduced Liver Fat in a 22 Week Mouse Model

To test causality, the team used a 22 week diet induced MASLD mouse model, then gave a subset of the mice Lipid 654 or Lipid 1256 enriched extracts for 8 weeks. Both treatments significantly reduced hepatic steatosis, meaning fat accumulation in the liver, and slowed histopathological disease progression compared with untreated mice. This fits a broader picture described in recent MASLD and gut microbiome pathogenesis research, which frames microbial metabolites as a therapeutic entry point for fatty liver disease. The mechanism here was not just less fat storage: the treated mice's livers, and human HepG2 liver cells treated in culture, showed increased mitochondrial DNA content and improved mitochondrial metabolic function, the cellular machinery that burns fat for energy rather than storing it.

Still a Mouse Study, With Immune Signals the Researchers Don't Yet Explain

This is a mechanistic study in mice and cultured cells, run out of a single lab, not a human clinical trial, so the size of any benefit in people is unknown, and no conflict of interest disclosure was available in the material reviewed for this piece. Broader reviews of MASLD pathogenesis and treatment models likewise stress that most microbiome-liver mechanisms are still at the animal-model stage. The researchers also found each lipid had a distinct fingerprint beyond fat metabolism: Lipid 1256 increased liver expression of Trem2, a gene involved in sensing lipids and already linked to protection against MASLD, while Lipid 654 instead altered a population of immune cells in the spleen, called CD4 positive effector memory T cells. Why the two closely related molecules diverge that way, and what it means for the immune system's role in fatty liver disease, is not yet resolved.

A Fiber to Liver Pathway Researchers Want to Test Next

The authors frame their results as evidence for a nutritional microbial axis: diet controls how much of this bacterial lipid the gut produces, and the lipid itself then acts on the liver's mitochondria to limit fat buildup. That is a mechanistic story worth watching, both because fiber is a lever anyone can pull and because the lipids in question are demonstrably present in human liver, not just mouse liver. But turning that into an actual treatment, or even solid dietary guidance, requires the step this study did not take: testing whether boosting glycine lipids through fiber, or through the lipids themselves, changes liver fat in humans, not mice.

Evidence rating

INVESTIGATIONAL — 75/100

Caveats:

• All therapeutic efficacy data are from mouse models; no human clinical trials have been conducted.
• Glycine lipids were administered via intraperitoneal injection, bypassing normal gut absorption — it is unknown whether oral or dietary routes produce the same hepatic effects.
• Fermentable fiber restored fecal glycine lipid levels ~7-fold but did not significantly raise hepatic glycine lipid levels in this study, leaving the fiber-to-liver pathway unconfirmed.
• Human liver tissue was used only to confirm the presence of these lipids, not to test any therapeutic effect.
• Findings have not yet been independently replicated in a separate laboratory or population.

Mouse intervention study (n = 13–15 per group) combined with cell culture experiments and limited human tissue sampling (n = 4). Demonstrates association and directional mechanistic evidence — including PGC-1α upregulation, mitochondrial DNA changes, and TREM2 induction — but causal claims in humans cannot be established from this design. Findings are consistent with prior work from the same research group but have not yet been independently replicated.

References

1. Liya Anto, Lidan Gao, Jaeeun Lee, et al. (2026). Fiber-dependent microbiome glycine lipids ameliorate steatotic liver disease in mice via mitochondrial enhancement. Gastro Hep Advances. https://doi.org/10.1016/j.gastha.2026.101064
2. Courtney L. Millar, Liya Anto, Chelsea Garcia, et al. (2022). Gut microbiome-derived glycine lipids are diet-dependent modulators of hepatic injury and atherosclerosis. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2022.100192
3. Bernd Schnabl, Christopher J. Damman, Rotonya M. Carr (2025). Metabolic dysfunction–associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations. Journal of Clinical Investigation. https://doi.org/10.1172/jci186423
4. Metabolic dysfunction-associated steatotic liver disease: Pathogenesis, model and treatment (Review) – PMC, NIH. NIH. https://pmc.ncbi.nlm.nih.gov/articles/PMC12549077/